Patents Examined by Anish Gupta
  • Patent number: 7786079
    Abstract: The invention relates to nonadepsipeptides and methods for their preparation and their use for the production of medicaments for the treatment and/or prophylaxis of diseases, in particular bacterial infectious diseases.
    Type: Grant
    Filed: April 19, 2007
    Date of Patent: August 31, 2010
    Assignee: AiCuris GmbH & Co. KG.
    Inventors: Franz Von Nussbaum, Nina Brunner, Rainer Endermann, Chantal Fuerstner, Elke Hartmann, Jacques Ragot, Guido Schiffer, Joachim Schuhmacher, Niels Svenstrup, Joachim Telser, Sonja Anlauf, Michael-Alexander Bruening
  • Patent number: 7786086
    Abstract: A nanostructure composed of a plurality of peptides, each peptide containing at least one aromatic amino acid, whereby one or more of these peptides is end-capping modified, is disclosed. The nanostructure can take a tubular, fibrillar, planar or spherical shape, and can encapsulate, entrap or be coated by other materials. Methods of preparing the nanostructure, and devices and methods utilizing same are also disclosed.
    Type: Grant
    Filed: September 8, 2005
    Date of Patent: August 31, 2010
    Assignee: Ramot at Tel-Aviv University Ltd.
    Inventors: Meital Reches, Ehud Gazit
  • Patent number: 7786072
    Abstract: The present invention provides novel stabilized crosslinked compounds having secondary structure motifs, libraries of these novel compounds, and methods for the synthesis of these compounds libraries thereof. The synthesis of these novel stabilized compounds involves (1) synthesizing a peptide from a selected number of natural or non-natural amino acids, wherein said peptide comprises at least two moieties capable of undergoing reaction to promote carbon-carbon bond formation; and (2) contacting said peptide with a reagent to generate at least one crosslinker and to effect stabilization of a secondary structure motif. The present invention, in a preferred embodiment, provides stabilized p53 donor helical peptides. Additionally, the present invention provides methods for disrupting the p53/MDM2 binding interaction comprising (1) providing a crosslinked stabilized ?-helical structure; and (2) contacting said crosslinked stabilized ?-helical structure with MDM2.
    Type: Grant
    Filed: June 9, 2005
    Date of Patent: August 31, 2010
    Assignee: President and Fellows of Harvard College
    Inventors: Gregory L. Verdine, Christian E. Schafmeister
  • Patent number: 7781405
    Abstract: The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids, (d) a relationship between the minimum number of net positive charges (pm) and the total number of amino acid residues (r) wherein 3pm is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to pt+1, except that when a is 1, pt may also be 1; and (f) at least one tyrosine or tryptophan amino acid.
    Type: Grant
    Filed: June 30, 2006
    Date of Patent: August 24, 2010
    Assignee: Cornell Research Foundation
    Inventor: Hazel H. Szeto
  • Patent number: 7776823
    Abstract: Provided are peptide and peptide consensus sequences, which inhibit bacterial growth and/or viral growth and mimic the activity of LL-37, CRAMP, and/or FALL-39. The peptides are useful as antimicrobials, anti-inflammatories and antiviral agents.
    Type: Grant
    Filed: October 20, 2004
    Date of Patent: August 17, 2010
    Assignee: The Regents of the University of California
    Inventors: Richard L. Gallo, Masamoto Murakami
  • Patent number: 7754691
    Abstract: Linear peptides with a C-terminus —OH group that are specific for one or more melanocortin receptors, and which may be used in the treatment of melanocortin receptor-mediated disorders, including a variety of body weight disorders including cachexia, and for treatment of inflammation, immune disorders and other conditions, diseases and syndromes, and pharmaceutical compositions including such linear peptides.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: July 13, 2010
    Assignee: Palatin Technologies, Inc.
    Inventor: Shubh D. Sharma
  • Patent number: 7754419
    Abstract: Provided are methods for determining the presence or amount of testosterone in a test sample, comprising ionizing all or a portion of the testosterone present in the sample to produce one or more testosterone ions that are detectable in a mass spectrometer. All or a portion of the testosterone present in the sample is ionized to produce one or more testosterone ions, which may be isolated and fragmented to produce precursor ions. A separately detectable internal testosterone standard can be provided in the sample. In a preferred embodiment, the reference is 2,2,4,6,6-d5 testosterone.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: July 13, 2010
    Assignee: Quest Diagnostics Investments Incorporated
    Inventors: Michael P. Caulfield, Darren A Carns, Richard E Reitz
  • Patent number: 7749725
    Abstract: The present invention relates to a method for screening drugs for use in treating hypertension using the tubular renin-angiotensinogen system identified by the present invention. The invention further relates to a method to diagnose sodium status and sensitivity in an individual by measuring urinary angiotensinogen or angiotensin-I.
    Type: Grant
    Filed: October 16, 2002
    Date of Patent: July 6, 2010
    Assignee: University of Utah Research Foundation
    Inventors: Andreas Rohrwasser, Terry Morgan, Jean-Marc Lalouel
  • Patent number: 7749969
    Abstract: N- or C-terminally modified small peptides having antiarrhythmic properties are disclosed, and in particular small peptides that possess improved pharmacokinetic properties such as having a reduced tendency to inhibit the activity of isozyme 3A4 of cytochrome P 450 oxidase. The invention further relates to uses of said compounds in the preparation of a medicament, and to pharmaceutical compositions comprising said compounds.
    Type: Grant
    Filed: July 7, 2006
    Date of Patent: July 6, 2010
    Assignees: Zealand Pharma A/S, Wyeth
    Inventors: Bjarne Due Larsen, Edward H. Kerns
  • Patent number: 7750117
    Abstract: It is disclosed here that a protein with a heat-labile specific binding activity can be stabilized with a saccharide compound with regard to the binding activity. To heat-stabilize the protein, it is mixed with a saccharide compound in a liquid suspension and the suspension is then dried to produce a solid that contains the protein and the saccharide. The saccharide compounds that possess the protein heat-stabilization activity include monosaccharides, disaccharides, polysaccharides, alkylated monosaccharides, alkylated disaccharides, alkylated polysaccharides, monosaccharide alcohols and alkylated monosaccharide alcohols.
    Type: Grant
    Filed: February 11, 2004
    Date of Patent: July 6, 2010
    Assignee: Wisconsin Alumni Research Foundation
    Inventors: Mark E. Cook, Mingder Yang, Mark R. Etzel
  • Patent number: 7745570
    Abstract: A novel peptide adhesive motif is described that requires no receptor or cross-links to achieve maximal adhesive strength. Several peptides with different degrees of adhesive strength have been designed and synthesized using solid phase chemistries. All peptides contain a common hydrophobic core sequence flanked by positively or negatively charged amino acids sequences.
    Type: Grant
    Filed: December 16, 2005
    Date of Patent: June 29, 2010
    Assignee: Kansas State University Research Foundation
    Inventors: John Tomich, Takeo Iwamoto, Xinchun Shen, Xiuzhi Susan Sun
  • Patent number: 7745408
    Abstract: A method for inducing melanogenesis in a human subject having a melanocortin 1 receptor (MC1R) variant allele associated with loss of or diminished receptor function comprises administering to said subject an amount of an ?-melanocyte stimulating hormone (?-MSH) analogue effective to induce melanogenesis by the melanocytes in the skin or other epidermal tissue of the subject.
    Type: Grant
    Filed: November 23, 2004
    Date of Patent: June 29, 2010
    Assignee: Clinuvel Pharmaceuticals Limited
    Inventor: Stuart Michael Humphrey
  • Patent number: 7745412
    Abstract: A method of changing or otherwise converting the biological activity of a PKC peptide agonist to a peptide antagonist is described. The method involves substituting one or more amino acid residues so as to effect a change in charge in the peptide and/or to otherwise make the sequence similar to a sequence derived from the PKC binding site on the RACK protein for the respective PKC enzyme. Methods of inhibiting the activity of a PKC enzyme, and various peptide antagonists of ?PKC are also disclosed.
    Type: Grant
    Filed: September 15, 2008
    Date of Patent: June 29, 2010
    Assignee: The Board of Trustees of the Leland Stanford Junior University
    Inventor: Daria Mochly-Rosen
  • Patent number: 7745401
    Abstract: A method of treating fungal infections by treatment with CAP37 peptides and derivatives thereof, including peptide analogs having serine or threonine substitutions at least one of the two cysteine residues therein. Other substitutions of the amino acid residues of the peptide are also contemplated.
    Type: Grant
    Filed: July 31, 2006
    Date of Patent: June 29, 2010
    Assignee: The Board of Regents of the University of Oklahoma
    Inventors: H. Anne Pereira, Paul Fidel
  • Patent number: 7745411
    Abstract: The present invention provides methods, compounds, pharmaceutical compositions, and kits for the augmentation of erythropoiesis by potentiating erythropoietin-induced differentiation with angiotensinogen, angiotensin I (AI), AI analogues, AI fragments and analogues thereof, angiotensin II analogues, AII fragments or analogues thereof or AII AT2 type 2 receptor agonists as a therapeutic adjunct. The method is useful for the treatment of congenital or acquired aplastic or hypoplastic anemia associated with chronic renal failure, end-stage renal disease, renal transplantation, cancer, AIDS, chemotherapy, radiotherapy, bone marrow transplantation and chronic diseases.
    Type: Grant
    Filed: June 6, 2007
    Date of Patent: June 29, 2010
    Assignee: University of Southern California
    Inventors: Kathleen Rodgers, Gere diZerega
  • Patent number: 7741362
    Abstract: The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.
    Type: Grant
    Filed: October 5, 2004
    Date of Patent: June 22, 2010
    Assignee: Siegfried Wurster
    Inventors: Jussi Tomperi, Paivi Hautamaki, Harri Salo, Mia Engstrom, Andrei Tauber, Anna-Marja Hoffren, Siegfried Wurster
  • Patent number: 7741268
    Abstract: The invention relates to the field of pharmaceutical formulations of follicle-stimulating hormone (FSH), luteinising hormone (LH), and mixtures of FSH and luteinising hormone (LH), and to methods of producing such formulations. The invention provides a liquid or freeze-dried formulation of FSH, or LH, or FSH and LH comprising a surfactant selected from Pluronic® F77, Pluronic F87, Pluronic F88 and Pluronic F68.
    Type: Grant
    Filed: April 2, 2004
    Date of Patent: June 22, 2010
    Assignee: Ares Trading S.A.
    Inventors: Fabrizio Samaritani, Piergiorgio Donati
  • Patent number: 7741105
    Abstract: Disclosed is a biomolecule chip and a fabrication method thereof. The biomolecule chip of the invention includes: a substrate; an insulating layer formed on the substrate; an adhesive layer formed on the insulating layer; a seed layer formed on the adhesive layer; an opening patterned at a predetermined location within the adhesive layer, the seed layer and the electroplating layer; and a biomolecule immobilized layer formed on the electroplating layer, the electroplating layer comprising a plasma-treated electroplating layer prior to the formation of the biomolecule immobilized layer. Accordingly, the immobilization of biomolecules onto the surface can be done more effectively by modifying the surface of the substrate in favor of biomolecules.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: June 22, 2010
    Assignee: Samsung Electronics Co., Ltd.
    Inventors: Young-il Kim, Moon-chul Lee, Jung-ho Kang, Tae-sik Park
  • Patent number: 7737252
    Abstract: This invention relates to new peptide-based compounds and their use in therapeutically effective treatments as well as for diagnostic imaging techniques. More specifically the invention relates to the use of such peptide-based compounds used as targeting vectors that bind to receptors associated with angiogenesis, in particular the ?v?3 integrin receptor. Such contrast agents may thus be used for diagnosis of for example malignant diseases, heart diseases, inflammation-related diseases, rheumatoid arthritis and Kaposi's sarcoma. Moreover such compounds may also be used in therapeutic treatment of these diseases.
    Type: Grant
    Filed: March 24, 2003
    Date of Patent: June 15, 2010
    Assignee: GE Healthcare AS
    Inventor: Alan Cuthbertson
  • Patent number: 7737111
    Abstract: The present invention concerns therapeutic agents that modulate the activity of TALL-1. In accordance with the present invention, modulators of TALL-1 may comprise an amino acid sequence Dz2Lz4 wherein z2 is an amino acid residue and z4 is threonyl or isoleucyl. Exemplary molecules comprise a sequence of the formulae (SEQ. ID. NO:100) a1a2a3CDa6La8a9a10Ca12a13a14, (SEQ. ID. NO:104) b1b2b3Cb5b6Db8Lb10b11b12b13b14Cb16b17b18 (SEQ. ID. NO:105) c1c2c3Cc5Dc7Lc9c10c11c12c13c14Cc16c17c18 (SEQ. ID. NO:106) d1d2d3Cd5d6d7WDd10Ld13d14d15Cd16d17d18 (SEQ. ID. NO:107) e1e2e3Ce5e6e7De9Le11Ke13Ce15e16e17e18 (SEQ. ID NO:109) f1f2f3Kf5Df7Lf9f10Qf12f13f14 wherein the substituents are as defined in the specification.
    Type: Grant
    Filed: November 10, 2005
    Date of Patent: June 15, 2010
    Assignee: Amgen, Inc.
    Inventors: Hosung Min, Hailing Hsu, Fei Xiong